Citi downgraded Bio-Rad to Neutral from Buy with a price target of $365, down from $400. The analyst says visibility remains limited on the company’s ability to achieve its life sciences revenue ramp given a lack of tangible catalysts. Citi also sees some risk to Bio-Rad’s second half of 2024 margin ramp as well. While the stock’s discounted valuation remains attractive, investors are unlikely to step in until execution is more consistent, contends the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: